Alembic Pharmaceuticals has announced its audited financial results for the quarter and financial year ended 31st March 2026. The company reported a robust performance, with an annual revenue from operations reaching ₹6,651.38 crore on a standalone basis. Reflecting this growth and financial stability, the Board of Directors has recommended a final dividend of ₹12 per equity share, representing a 600% payout, subject to approval at the upcoming Annual General Meeting.
Fiscal Year 2026 Financial Highlights
Alembic Pharmaceuticals has concluded a successful financial year, demonstrating significant operational efficiency. For the full year ended 31st March 2026, the company achieved standalone revenue of ₹6,651.38 crore, compared to ₹6,032.63 crore in the previous year. The standalone net profit for the period stood at ₹640.42 crore, underscoring consistent growth despite various market challenges.
Dividend Recommendation
Recognizing the company’s strong financial health and commitment to delivering value to its stakeholders, the Board of Directors has recommended a dividend of ₹12 per equity share (having a face value of ₹2 each). This translates to a 600% dividend payout for the financial year 2025-26. The payment of this dividend is subject to the necessary approval from shareholders at the company’s ensuing Annual General Meeting.
Consolidated Performance Overview
On a consolidated basis, the company exhibited even stronger figures, reporting annual revenue of ₹7,344.90 crore and a net profit after non-controlling interests of ₹674.77 crore. These figures reflect the company’s integrated approach and the contribution of its diverse global subsidiaries to the overall group performance.
Operational Insights
Throughout the fiscal year, Alembic navigated complex economic factors, including the implementation of new labour codes and strategic asset management, such as the reclassification of the Sikkim manufacturing facility. Despite these adjustments, the company maintained a healthy debt-to-equity ratio of 0.20, indicating a solid balance sheet and effective capital management strategies as it moves into the new financial year.
Source: BSE
